Drug Development

Mestag Therapeutics begins a human trial for MST-0312, a novel antibody designed to force tumors to build their own immune-boosting structures.

SERB Pharma's acquisition of Idefirix® rights offers new hope to thousands of highly sensitized patients previously unable to receive a kidney transplant.

Mineralys Therapeutics' lorundrostat shows promise for millions with uncontrolled blood pressure and kidney disease, targeting a key hormonal driver.

Alaunos Therapeutics reports positive preclinical data for its oral metabolic drug, but with a perilous financial runway, the race for survival is on.

Biotheryx's novel protein degrader, BTX-9341, shows impressive safety and efficacy in patients who have progressed on standard therapies.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

With 12% weight loss in a pivotal trial, Vincentage Pharma's VCT220 pill is set to challenge injectables and reshape China's obesity drug market.

A key workshop aims to bridge the gap between FDA policy and patient needs, seeking to streamline therapy development for millions with rare diseases.

Early human trial data for a new drug, UDP-003, suggests it can safely remove toxic cholesterol, a key step toward reversing arterial plaque buildup.

With a new CEO, a half-billion-dollar war chest, and a novel drug pipeline, Damora Therapeutics is making an aggressive play to redefine blood cancer treatment.

Pharma and COVID-response leader John Young joins UCSF's QBI to translate its cutting-edge protein science into transformative therapies and partnerships.

A Belgian firm's new biologic gel for diabetic foot ulcers gets a key FDA green light, offering hope against a leading cause of amputations.

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

OncLive® unveils its 2026 class of inductees, 14 visionaries whose groundbreaking work is transforming the future of oncology and bringing hope to millions.

UWorld and the Goldwater Foundation award 93 top students, fueling the pipeline of medical researchers poised to tackle society's biggest health challenges.

A new drug shows major promise for a painful heart condition, with pivotal study results accepted by a top journal and a final-stage trial speeding ahead.

A new obesity drug shows 19.3% weight loss with remarkably few side effects, while also improving blood pressure, cholesterol, and even bone density.

As EyePoint's losses widen to fund its lead drug, DURAVYU, the company is on the cusp of pivotal trial results that could redefine retinal disease treatment.

Medical tech giant Convatec unveils a new arsenal of advanced wound care solutions, using nitric oxide and placental tech to combat hard-to-heal injuries.

A new blood test could tell you if GLP-1 drugs will work for you before you start, a major leap for precision medicine in the booming obesity market.